We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| LumiraDx Ltd | NASDAQ:LMDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.016 | 0.014 | 0.0146 | 0 | 01:00:00 |
From Jun 2022 to Jun 2024
By Dean Seal
LumiraDx Ltd. said it received emergency use authorization from the U.S. Food and Drug Administration for its multiplex test that can detect and differentiate strains of influenza and Covid-19.
The London-based company said Monday morning that it would immediately commence commercial shipping of the test, which can simultaneously identify influenza A, influenza B and Covid-19 infections within 20 minutes or less.
LumiraDx launched the test in the European Union last June and will now begin its commercialization efforts in the U.S. and U.K.
"With the limited number of direct amplification multi-analyte tests available, we believe that this test will become a fundamental tool for the detection and differentiation of SARS-CoV-2 from influenza," said Sanjay Malkani, president of LumiraDx's molecular-diagnostics business.
Shares rose 6.7%, to $1.28, in premarket trading Monday.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 06, 2023 08:44 ET (13:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year LumiraDx Chart |
1 Month LumiraDx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
